Slingshot Insights | Teva.ta Overview

TEVA.TA Overview

Upcoming Projects (TEVA.TA)

Don’t see a project related to the company you care about? Create your own!

Upcoming & Overdue Catalysts (TEVA.TA)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (TEVA.TA)

New business venture focused on generics in Japan to be established in or after April 2016; owned 51% by Teva and 49% by Takeda
Tickers: TEVA, TEVA.TA, TKPYY
Occurred on: Apr 01, 2016
TEVA Launches Generic Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States
Tickers: TEVA, TEVA.TA
Occurred on: Jan 05, 2016
Teva and Active Biotech discontine high doses of laquinimod in two ongoing studies in multiple sclerosis after the occurrence of cardiovascular events, none of which was fatal, in eight patients; CONCERTO and ARPEGGIO Trials Continue Study
Tickers: TEVA, TEVA.TA, ACTI.F
Occurred on: Jan 04, 2016
TEVA secures additional $658M in net proceeds from its equity offering via the full exercise of the underwriters over-allotment of 5.4M ADSs and 337.5K Mandatory Convertible Preferred Shares, increasing the company's take to $7.24B
Tickers: TEVA, TEVA.TA
Occurred on: Jan 03, 2016

Strategic Initiatives (TEVA.TA)

Don’t see a strategic initiative related to the company you care about? Create your own!